×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CUE – cue biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
04:17 pm
cue
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
High
Report
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
04:05 pm
cue
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
High
Report
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/14
08:22 am
cue
Cue Biopharma Announces Strategic Organizational Transition [Yahoo! Finance]
Neutral
Report
Cue Biopharma Announces Strategic Organizational Transition [Yahoo! Finance]
11/14
08:00 am
cue
Cue Biopharma Announces Strategic Organizational Transition
Medium
Report
Cue Biopharma Announces Strategic Organizational Transition
11/12
08:00 am
cue
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
High
Report
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
11/8
01:33 pm
cue
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting [Yahoo! Finance]
Medium
Report
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting [Yahoo! Finance]
11/8
01:30 pm
cue
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Medium
Report
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
10/8
06:45 am
cue
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% [Yahoo! Finance]
High
Report
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:01 pm
cue
Form 10-Q Cue Biopharma, Inc. For: Sep 30
High
Report
Form 10-Q Cue Biopharma, Inc. For: Sep 30
11/14
04:01 pm
cue
Form 8-K Cue Biopharma, Inc. For: Nov 14
High
Report
Form 8-K Cue Biopharma, Inc. For: Nov 14
10/8
04:00 pm
cue
Form 8-K Cue Biopharma, Inc. For: Oct 08
Low
Report
Form 8-K Cue Biopharma, Inc. For: Oct 08
10/7
05:08 pm
cue
Form SCHEDULE 13G/A Cue Biopharma, Inc. Filed by: Bleichroeder LP
Medium
Report
Form SCHEDULE 13G/A Cue Biopharma, Inc. Filed by: Bleichroeder LP
10/4
04:00 pm
cue
Form 8-K Cue Biopharma, Inc. For: Oct 02
High
Report
Form 8-K Cue Biopharma, Inc. For: Oct 02
9/27
04:17 pm
cue
Form 8-K Cue Biopharma, Inc. For: Sep 26
High
Report
Form 8-K Cue Biopharma, Inc. For: Sep 26
9/27
04:06 pm
cue
Form 424B5 Cue Biopharma, Inc.
Medium
Report
Form 424B5 Cue Biopharma, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/2
Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference
6.2%
12/21 Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE) [Yahoo! Finance News] 6.2%
1/7 Does Market Volatility Impact Cue Biopharma, Inc.'s (NASDAQ:CUE) Share Price? [Yahoo! Finance News] 7.7%
4/28 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%
7/25 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 8.2%
4/8 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 9.0%
6/7 Form 4 Cue Biopharma, Inc. For: Jun 06 Filed by: PASSERI DANIEL R 13.8%
4/20 Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer 13.9%
2/19 Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit 14.5%
3/19 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 24.3%
12/21 Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE) [Yahoo! Finance News] 6.2%
1/7 Does Market Volatility Impact Cue Biopharma, Inc.'s (NASDAQ:CUE) Share Price? [Yahoo! Finance News] 7.7%
4/28 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%
7/25 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 8.2%
4/8 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 9.0%
6/7 Form 4 Cue Biopharma, Inc. For: Jun 06 Filed by: PASSERI DANIEL R 13.8%
4/20 Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer 13.9%
2/19 Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit 14.5%
3/19 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 24.3%
TOP News Decliners
9/18
Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
-5.2%
6/5 Form 8-K Cue Biopharma, Inc. For: Jun 05 -6.0%
7/9 Form 10-Q/A Cue Biopharma, Inc. For: Mar 31 -6.2%
2/14 Form SC 13G Cue Biopharma, Inc. Filed by: Avoro Capital Advisors LLC -6.5%
3/26 Form 4 Cue Biopharma, Inc. For: Mar 24 Filed by: Pienta Kenneth -7.1%
3/6 Cue Biopharma Inc (NASDAQ: CUE) had its price target raised by analysts at JMP Securities from $22.00 to $30.00. They now have an "outperform" rating on the stock. -7.9%
3/11 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.0%
12/27 Form 4 Cue Biopharma, Inc. For: Dec 23 Filed by: MARLETT CHRISTOPHER A -8.9%
3/17 Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights -13.7%
3/12 Form 10-K Cue Biopharma, Inc. For: Dec 31 -20.4%
6/5 Form 8-K Cue Biopharma, Inc. For: Jun 05 -6.0%
7/9 Form 10-Q/A Cue Biopharma, Inc. For: Mar 31 -6.2%
2/14 Form SC 13G Cue Biopharma, Inc. Filed by: Avoro Capital Advisors LLC -6.5%
3/26 Form 4 Cue Biopharma, Inc. For: Mar 24 Filed by: Pienta Kenneth -7.1%
3/6 Cue Biopharma Inc (NASDAQ: CUE) had its price target raised by analysts at JMP Securities from $22.00 to $30.00. They now have an "outperform" rating on the stock. -7.9%
3/11 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.0%
12/27 Form 4 Cue Biopharma, Inc. For: Dec 23 Filed by: MARLETT CHRISTOPHER A -8.9%
3/17 Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights -13.7%
3/12 Form 10-K Cue Biopharma, Inc. For: Dec 31 -20.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: